Foghorn Therapeutics (FHTX) Interest Coverage Ratio (2019 - 2026)
Foghorn Therapeutics' (FHTX) quarterly Interest Coverage Ratio came in at 0.35 in Q1 2026, up 95.72% year-on-year from 0.18 in Q1 2025, and up 97.5% quarter-over-quarter from 14.19 in Q4 2025.
Foghorn Therapeutics (FHTX) Interest Coverage Ratio (2019 - 2026) Analysis & Trends
Foghorn Therapeutics' Interest Coverage Ratio history runs 8 years deep, the most recent figure standing at 0.35 for Q1 2026.
- On a quarterly basis, Interest Coverage Ratio rose 95.72% year-over-year to 0.35 in Q1 2026; TTM through Mar 2026 was 1.4, a 77.83% increase from a year earlier, with the FY2025 full-year figure at 0.46, up 25.38% from the prior year.
- Interest Coverage Ratio rose to 0.35 in Q1 2026 per FHTX's latest filing, from 14.19 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 0.18 in Q4 2023 and bottomed at 954.08 in Q3 2024.
- The 5-year median for Interest Coverage Ratio is 9.02 (2023), against an average of 78.72.
- Across the five-year window, Interest Coverage Ratio slumped 10479.17% in 2024 and surged 99.92% in 2025, its largest moves.
- Year by year, Interest Coverage Ratio stood at 3.19 in 2022, then surged by 94.42% to 0.18 in 2023, then plunged by 4903.98% to 8.91 in 2024, then slumped by 59.22% to 14.19 in 2025, then surged by 97.5% to 0.35 in 2026.
- Per Business Quant, the three latest FHTX Interest Coverage Ratio figures stand at 0.35 (Q1 2026), 14.19 (Q4 2025), and 0.73 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.60 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -0.22 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -0.38 |
| 10 | Foghorn Therapeutics | 352.57 Mn | 263.66 Mn | - | -0.35 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.35 |
| Dec 31, 2025 | -14.19 |
| Sep 30, 2025 | -0.73 |
| Jun 30, 2025 | -0.35 |
| Mar 31, 2025 | -8.30 |
| Dec 31, 2024 | -8.91 |
| Sep 30, 2024 | -954.08 |
| Jun 30, 2024 | -78.79 |
| Mar 31, 2024 | -56.16 |
| Dec 31, 2023 | -0.18 |
| Sep 30, 2023 | -9.02 |
| Jun 30, 2023 | -11.78 |
| Mar 31, 2023 | -11.56 |
| Dec 31, 2022 | -3.19 |
| Mar 31, 2022 | -23.17 |
| Dec 31, 2021 | -3.30 |
| Sep 30, 2021 | -0.35 |
| Jun 30, 2021 | -0.30 |
| Mar 31, 2021 | -9.76 |
| Dec 31, 2020 | -8.56 |